AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00910871
Drug: Background Regimen (BR) for MDR-TB
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
Trial: NCT01304953
Drug: Group P+P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia.
Trial: NCT01304953
Drug: Group P+T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
Trial: NCT01304953
Drug: Group S+P
RxNorm normalized name: P & S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia.
Trial: NCT01304953
Drug: Group S+T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.
Trial: NCT04235426
Drug: 30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
Trial: NCT02359552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01127048
Drug: Suppositories containing Ivy leaves dry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppositories containing Ivy leaves dry extract
Trial: NCT01127048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppositories containing no Ivy leaves dry extract
Trial: NCT02063594
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
Trial: NCT01310127
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
Trial: NCT01310127
Drug: Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
Trial: NCT03639857
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The topical corticosteroid will be used to treat the lesion in this study arm.
Trial: NCT00024440
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03575247
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term use of glucocorticoids
Trial: NCT02391571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 day placebo run in prior to test and active drug phase of study
Trial: NCT00350077
Drug: Intravenous Vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin C IV during 24 hour period following burn
Trial: NCT00558012
Drug: Intravenous zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid 5.0 mg once
Trial: NCT03397121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Trial: NCT01005862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00856791
Drug: ON 01910.Na
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00455000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04020653
Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD
Trial: NCT04020653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
Trial: NCT04020653
Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID
Trial: NCT03872843
Drug: Norco 5milligram-325milligram Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
Trial: NCT03872843
Drug: Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
Trial: NCT02459197
Drug: Administration of Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment is given as add-on therapy to patient's regular analgesic treatment
Trial: NCT03369314
Drug: octaplasLG®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data will be collected in all patients who have received at least one infusion of octaplasLG®
Trial: NCT02785900
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
Trial: NCT02710578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
Trial: NCT01919255
Drug: Picolight + Coolprep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]
Trial: NCT01919255
Drug: Picolight + Clicolon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
Trial: NCT00488761
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02724163
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A nitrogen mustard alkylating agent from the oxazaphosphorine group
Trial: NCT02946788
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BPX-01 1 or 2% topical gel will be applied to face once daily
Trial: NCT03118817
Drug: HM95573
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops
Trial: NCT00169104
Drug: saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
Trial: NCT00055445
Drug: IdB 1016
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01726075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop per eye twice a day during 24 months
Trial: NCT05088733
Drug: Yang Yin Fu Zheng Jie Du therapy
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
Trial: NCT02061748
Drug: Observational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective Chart Review
Trial: NCT04006704
Drug: D/C/F/TAF FDC placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
Trial: NCT01028404
Drug: NN1952
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
Trial: NCT01028404
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
Trial: NCT01028404
Drug: NN1952
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
Trial: NCT00905424
Drug: Antidepressant + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
Trial: NCT00595543
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
Trial: NCT00595543
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
Trial: NCT00595543
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
Trial: NCT04229706
Drug: Xiang Ju Ru Pi Ning capsule placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xiangjurupining capsule,8 capsule,tid,3 months.
Trial: NCT01852513
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00371813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
Trial: NCT02539719
Drug: SC-003
RxNorm normalized name: tobramycin 0.003 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00520299
Drug: ADI PEG 20
RxNorm normalized name: PEG-20 stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
Trial: NCT03749616
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
Trial: NCT03749616
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
Trial: NCT02929862
Drug: LYC-55716
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
Trial: NCT04457011
Drug: High dose Susu Xiao'er Zhike Granules 1 bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
Trial: NCT04457011
Drug: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 1.01 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
Trial: NCT00278863
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05857410
Drug: Dexmetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmetomidine (H20183219) 0.4μg / (kg·min)；
Trial: NCT01871077
Drug: PRO-156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
Trial: NCT02160548
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard management for OP poisoning
Trial: NCT02160548
Drug: Standard care+ 2.5 mg Salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin respiratory solution 2.5 mg
Trial: NCT02160548
Drug: Standard care+ 5 mg Salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin respiratory solution 5 mg
Trial: NCT01204086
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
Trial: NCT03789097
Drug: Flt3L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an immune cell growth factor. CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains a nominal 2.5 mg/mL CDX-301 protein in a 1 mL volume of buffered solution composed of sodium phosphate and sodium chloride, with a pH of 7.0.
Trial: NCT00108290
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03162185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group participants (n = 30) will receive a placebo for 7 days.
Trial: NCT04577794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder and solvent for oral solution reconstituted prior to use.
Trial: NCT00073450
Drug: Farnesyl Protein Transferase Inhibitor
RxNorm normalized name: farnesyl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01275443
Drug: 300mg TMC278LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg TMC278LA intramuscular injection
Trial: NCT01275443
Drug: 150mg TMC278LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg TMC278LA intramuscular injection
Trial: NCT01275443
Drug: 1200mg TMC278LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg TMC278LA intramuscular injection
Trial: NCT04338477
Drug: Nephrosolid tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adminstration of drug
Trial: NCT00647972
Drug: Zyprexa® Tablets 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg, single dose fasting
Trial: NCT00280592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
Trial: NCT01689441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00823238
Drug: ceftazidime and tobramycin
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00823238
Drug: inhaled tobramycin
RxNorm normalized name: tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01345656
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
Trial: NCT01345656
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
Trial: NCT01345656
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 10 mg BAY94-8862 tablet for duration of 4 weeks
Trial: NCT01345656
Drug: BAY94-8862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
Trial: NCT01345656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for duration of 4 weeks
Trial: NCT01345656
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
Trial: NCT03199950
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral 2dd (08.00am - 10.00pm)
Trial: NCT01718613
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
Trial: NCT02916134
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics.
Trial: NCT00661635
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
Trial: NCT00661635
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
Trial: NCT00661635
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
Trial: NCT00069849
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01126684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily for six months
Trial: NCT01721447
Drug: Optison echocardiography contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
Trial: NCT01619878
Drug: Artemether-lumefantrine (COA566)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dispersible tablet taken orally twice a day during 3 days.
Trial: NCT03518086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04639960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve weeks of placebo treatment.
Trial: NCT04491136
Drug: ARNI
RxNorm normalized name: Arnica
DrugBank: Arnica montana flower (DB14343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study
Trial: NCT00002519
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03284853
Drug: GANFORT®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sterile ophthalmic solution